Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma.

摘要: The generation of murine monoclonal antibodies reactive with human leukemia and lymphoma cells has recently led to clinical trials that have begun evaluate the use these reagents in treatment various leukemias lymphomas. Several studies demonstrated infusion antibody can cause rapid specific clearance leukemic from peripheral blood. Intravenously administered also rapidly binds bone marrow lymphoblasts, one instance, resulted partial regression tumor cell infiltrates lymph nodes skin. Unfortunately, clinically significant responses not general been achieved, but identified factors result development resistance antibody-mediated lysis vivo. These include presence circulating antigen, antigenic modulation, reactivity normal cells, immune response antibody, inefficiency natural effector mechanisms. Current research is now being directed towards developing methods circumvent each obstacles. Future utilizing vitro or different specificity may demonstrate greater therapeutic efficacy. In addition, be used as carriers other cytotoxic agents conjunction will reduce total load. Monoclonal represent new powerful near future become an additional modality for patients malignant disease.